Application of interphase fluorescence in situ hybridization and sequencing analysis in imatinib treatment of patients with chronic myeloid leukemia in chronic phase
AIM: To explore the significance of interphase fluorescence in situ, hybridization (I-FISH) and sequencing analysis in evaluating the curative effect, drug resistance and prognosis of imatinib treatment for patients with chronic myeloid leukemia (CML) in chronic phase (CP). METHODS: The tumor load was detected in 18 CML-CP cases with complete cytogenetic remission (CCR), who were treated with imatinib by dual-color and dual-fusion I-FISH (D-FISH). The point mutation of Abl kinase domain was analyzed in the patients with positive result of D-FISH by sequencing. RESULTS: In normal control, the cutoff rate of D-FISH was 0.73%. The positive rate of D-FISH was 8/18 (44%) and 2 point mutations (E255K and T315I) of Abl kinase domain were found in 2 cases respectively. CONCLUSION: Combination of I-FISH and sequencing analysis can be used as a sensitive and specific tool not only to monitor the tumor load in CML, but also to evaluate the curative effect, drug resistance and prognosis of imatinib treatment.
NETL
NSTL
万方数据
维普
